The Regeneron Pharmaceuticals Inc. (REGN) Given a $447.00 Price Target by Piper Jaffray Cos. Analysts

The Regeneron Pharmaceuticals Inc. (REGN) Given a $447.00 Price Target by Piper Jaffray Cos. Analysts

Piper Jaffray Cos. set a $447.00 price target on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research note issued to investors on Thursday. The brokerage currently has a a hold rating on the biopharmaceutical company’s stock.

REGN has been the subject of a number of other reports. Roth Capital restated a buy rating and issued a $520.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 4th. Leerink Swann reiterated a buy rating and set a $530.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 21st. Goldman Sachs Group Inc. reiterated a buy rating and set a $521.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Chardan Capital reiterated a sell rating and set a $325.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 30th. Finally, Canaccord Genuity reiterated a hold rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, June 17th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $480.09.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 1.21% during midday trading on Thursday, hitting $371.23. 173,010 shares of the stock were exchanged. The stock has a market capitalization of $38.84 billion, a price-to-earnings ratio of 57.91 and a beta of 1.31. Regeneron Pharmaceuticals has a 1-year low of $329.09 and a 1-year high of $592.59. The firm’s 50 day moving average is $398.39 and its 200-day moving average is $392.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.17. The business earned $1.21 billion during the quarter, compared to analysts’ expectations of $1.24 billion. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The business’s quarterly revenue was up 21.4% on a year-over-year basis. During the same period last year, the company posted $2.89 earnings per share. On average, analysts predict that Regeneron Pharmaceuticals will post $11.02 EPS for the current year.

In related news, Director Joseph L. Goldstein sold 2,125 shares of the company’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the sale, the director now directly owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 10.40% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Wellington Management Group LLP raised its stake in Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares in the last quarter. Winslow Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $291,760,000. FMR LLC raised its position in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares during the period. Capital World Investors raised its position in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock valued at $2,558,678,000 after buying an additional 312,008 shares during the period. Finally, Emerald Acquisition Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $87,319,000. Institutional investors own 68.16% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Related posts

Leave a Comment